Close Menu

Bruker's Losses, Revenues Rise in Q3

Bruker BioSciences this week reported revenues of $63 million for the third quarter ending Sept. 30, up over the $57 million reported for the year-ago quarter. The results reflected a charge of $6.4 million for the July 1 merger of Bruker Daltonics and Bruker AXS, and results from prior periods are historical combined reports of the two previously separate companies. This is the first quarter for which the report reflects numbers from the completed merger.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.